All News

Alnylam's Givosiran Looks Positive Overall in Phas

Despite releasing positive data on its Phase III ENVISION trial, Alnylam Pharmaceuticals stock dropp
Read More

Gene-editing startup Beam bags $135M in series B t

The Cambridge, Massachusetts, biotech—which was one of our Fierce 15 winners last year—says the new
Read More

Merck KGaA admits to ‘challenging’ 2018, as curren

Germany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency h
Read More

Roche Study Shows AI Can Detect Severity of Diabet

The study, Roche said, adds to the growing amount of scholarly information about the use of artifici
Read More

Alnylam to seek approval for second RNAi drug

Alnylam thinks it has strong enough clinical data for its gene-silencing drug for rare disease acute
Read More

Treating triple-negative breast cancer by repurpos

Triple-negative breast cancer patients lack three common markers—estrogen, progesterone and HER2—mak
Read More

India - On the way to becoming an attractive new d

In one of the most unprecedented events of this century, the Covid 19 pandemic caused catastrophic g
Read More


;